Many stakeholders play a role in ensuring access for patients; providers in the community and academic settings, leaders at infusion clinics, decision-makers within IDNs, health plans, trade and distribution, officials from regulatory/HTA agencies, professional societies, compendia organizations, and advocacy organizations. In order to optimize your KOL Identification and Outreach plan, our team will develop a map of potential influencers across Academic Hospitals and Large Community Oncology Practices with the potential to act as champions for your product in support of increased access for patients.
As a first step, our expert team will conduct secondary research to understand provider reach, including completion of a medical literature review to identify influential publishers and a review of CME events/major conferences to identify influential speakers/presenters with expertise and influence in disease and who have the capacity to impact access, coverage, and reimbursement for the product in support of increased access for patients through a quantitative peer-nomination process.
Following the secondary research, identified HCPs will be validated through primary market research quantitative interviews to execute the peer-nomination process to identify key influencers and opinion leaders in the disease, specifically as it relates to access for your product.
Innovation Partners’ deep expertise in oncology, hematology, and rare diseases guides the creation of a custom and comprehensive map of individuals and organizations who have the capacity to impact access, coverage, and reimbursement for your portfolio. Whether you are bringing your first product to market or entering a new therapeutic area, our team will leverage our deep relationships with influencers to identify the key decision-makers you need to engage to ensure future success.